Autopsy report · NCT00485563
A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
Cause of deathSlow enrollment
“Changes in treatment paradigm resulted in a lower than expected rate of accrual.”
Life of this trial
- Ran for about 1 year 9 months before it stopped.
- 12 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Endocyte
- Sponsor type
- Industry
- Conditions
- Renal Cell Carcinoma
- Interventions
- EC90 (KLH-FITC); GPI-0100; EC17 (Folate-FITC); Interleukin-2; Interferon-alpha
- Participants
- 12
- Sites
- 3
- Countries
- United States
Trials that died the same way
- Docetaxel Intermittent-Erlotinib (Tarceva®) In Metastatic Non Small Cell Lung Cancer (NSCLC)
“The low accrual rate of the study (30% of the expected accrual rate)/Low efficacy in both treatment arms.” - Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
“Slow accrual and changes in clinical practice” - Pembrolizumab and Olaparib in Cervical Cancer Patients
“Poor accrual related to change in standard of care treatment for this population.” - Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
“slow accrual - the 1 patient accrued did not go on treatment” - Pre-operative Zoledronate in Triple Negative Breast Cancer
“The study stopped prematurely due to the low accrual rate”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.